Altimmune Inc (NQ: ALT )
4.090 -0.120 (-2.85%) Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Headline News about Altimmune Inc
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
June 27, 2021
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big...
Exposures Product Safety
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
June 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,...
Exposures COVID-19 Product Safety
Pre-open movers U.S. stock futures traded mixed in early pre-market trade after the Wall Street closed mixed in the previous session. Investors are awaiting earnings results from...
Exposures Interest Rates
Altimmune's Intranasal COVID-19 Vaccine Candidate Neutralizes South African Variant, Animal Study Shows
May 26, 2021
Altimmune Inc (NASDAQ: ALT) has announced new results from a preclinical study of AdCOVID, the company's vaccine candidate. Data demonstrated that the vaccine...
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
May 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:...
ALTIMMUNE INC (ALT) Q1 2021 Earnings Call Transcript
May 17, 2021
Altimmune's Intranasal COVID-19 Vaccine Candidate Shows Sterilizing Immunity After Single Dose
May 10, 2021
Altimmune Inc (NASDAQ: ALT) has announced positive results from a preclinical study evaluating its intranasal COVID-19 vaccine candidate, AdCOVID, in a SARS-...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following